Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance studyMichael J Koren
Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
J Am Coll Cardiol 44:1772-9. 2004
....
- Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial
Michael J Koren
Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
Am J Med 118:16-21. 2005
..These results indicate that usual-care treatment was not equivalent to targeted statin therapy, even in a trial conducted to minimize potential bias owing to traditional patient selection and trial design methods...
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKDMichael J Koren
Jacksonville Center for Clinical Research, Jacksonville, FL 32216, USA
Am J Kidney Dis 53:741-50. 2009
....
- Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)
Michael J Koren
Jacksonville Center for Clinical Research, Jacksonville, Florida 32216, USA
J Am Coll Cardiol 49:1027-34. 2007
..This report describes safety and tolerability data from 746 chronic angina patients treated in the ROLE (Ranolazine Open Label Experience) program...
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J Koren
Jacksonville Center for Clinical Research, FL, USA
Lancet 380:1995-2006. 2012
..We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients with hypercholesterolaemia in the absence of concurrent lipid-lowering treatment...
- Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years
Michael J Koren
Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
Clin Cardiol 32:256-63. 2009
..High-dose statin therapy may be underutilized in aged patients due to doubts about efficacy and safety...
- Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia
Michael J Koren
Jacksonville Center for Clinical Research, Jacksonville, FL, USA
Am J Health Syst Pharm 68:818-27. 2011
..The efficacy and safety of conivaptan administered via 30-minute i.v. infusion to patients with euvolemic or hypervolemic hyponatremia were evaluated...
- Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective
Robert J Straka
University of Minnesota, Minneapolis, MN, USA
Curr Med Res Opin 23:1517-29. 2007
..The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations...
- Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial
John D Parker
Department of Medicine, University Health Network and Mount Sinai Hospitals, University of Toronto, Ontario, Canada
Crit Care Med 35:1863-8. 2007
..g., sildenafil) might need intravenous nitroglycerin (NTG) treatment. This study determined if, and at what dose, intravenous NTG could be administered safely to men with coronary artery disease who had recently ingested sildenafil...
- Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
Jalal K Ghali
Division of Cardiology, Wayne State University, 4201 St Antoine, Detroit, Michigan 48201, USA
J Clin Endocrinol Metab 91:2145-52. 2006
..Hyponatremia [serum sodium concentration ([Na(+)]), <135 mEq/liter] is the most common fluid and electrolyte abnormality among hospitalized patients. It is frequently caused by the inappropriate release of arginine vasopressin...
